Purav Patel - 10 Dec 2024 Form 4 Insider Report for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Role: Director
Signature: /s/ Narayan Prabhu, attorney-in-fact for Purav Patel
Issuer symbol: RVPH
Transactions as of: 10 Dec 2024
Net transactions value: $0
Form type: 4
Filing time: 12 Dec 2024, 16:35:57 UTC
Previous filing: 14 Nov 2023
Next filing: 19 Dec 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVPH	Stock Option (right to buy)	Award	$0	+8,200		$0.000000	8,200	10 Dec 2024	Common Stock, par value $0.0001 per share	8,200	$2.52	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock ("Common Stock") subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

Content

This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock ("Common Stock") subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.